

Ultrasmall gadolinium manganese oxide nanoparticles as MRI contrast agent

Badrul Alam Bony¹, Wenlong Xu¹, Tirusew Tegafaw Mengesha¹, Chorong Kim¹, Sung June Kim¹, Md. Wasi Ahmad¹, and Gang Ho Lee¹
¹Chemistry, Kyungpook National University, Daegu, Korea

Introduction

Magnetic resonance imaging (MRI) is a powerful and noninvasive diagnostic technique of the human anatomy on the basis of superior spatial resolution and contrast. A large number of MRI techniques are performed employing gadolinium complexes and gadolinium nanoparticles. However, doped or alloy nanoparticles can show better contrast with enhancing relaxivity. For this purpose, we have developed ultra-small gadolinium manganese oxide nanoparticles, which are abbreviated as GdMnO₃. The average size of prepared nanoparticles is of 2 to 3 nm, which can be dispersed homogeneously. They were coated with biocompatible and water soluble D-glucuronic acid. It shows high relaxivity than normal ultra-small gadolinium oxide nanoparticles. Moreover, in vivo and in-vitro tests of the sample solution, indicated clear dose-dependent contrast enhancements in both T₁ and T₂ map images, showing that the nanoparticles can be used as both T₁ and T₂ contrast agents.

Material and Methods

In order to synthesize D-glucuronic acid coated ultra-small GdMnO₃ nanoparticles, ultra-small GdMnO₃ nanoparticles were first synthesized and then, D-glucuronic acid was used to coat the ultra-small nanoparticles. 2.5 mmol gadolinium chloride hydrate (GdCl₃·xH₂O) and 2.5 mmol manganese chloride dihydrate (MnCl₂·4H₂O) were added into 40 ml triethylene glycol and the mixture was stirred till dissolved well. Then 15 mmol NaOH was added and heated to reflux at 80 °C for 2 h with magnetic stirring. After 2 h, 5 ml H₂O₂ was added and continued heating at 80 °C for another 2h. To coat the nanoparticles, 5 mmol D-glucuronic acid was added to the reaction solution. The reaction solution was heated to reflux at 80 °C for a further 6 h with magnetic stirring. After cooling to room temperature, it was washed three times using ethanol to remove unreacted Gd³⁺, Mn³⁺, Cl⁻ ions from the reaction solution. After washing for three times, the nanoparticles were then collected. Half of the yielded nanoparticles were used for measuring TEM, relaxivity, cytotoxicity and MR image measurements, and the remainder was dried in air to obtain a powder sample for the other characterizations. All chemicals were purchased from Aldrich.

Results and Discussion

Figure 1 shows a high resolution transmission electron microscope (HRTEM) image of the D-glucuronic acid coated ultra-small GdMnO₃ nanoparticles. The size of the ultrasmall GdMnO₃ nanoparticles is around 3.0 nm. In figure 2, the XRD pattern proves the formation of GdMnO₃ nanoparticles. Surface coating by D-glucuronic acid is confirmed from the FTIR absorption spectrum of powder sample (Figure 3). GdMnO₃ nanoparticles can efficiently induce longitudinal relaxation of water protons. In fact, a high r₁ and r₂ value were observed (Figure 4). Moreover, In vitro, T₁ and T₂ map images were measured (Figure 5). They show clear dose-dependent contrast enhancements, which are due to the increased relaxation of water protons with increased dose. In vivo image of liver and kidney were showed in Figure 7 & 8 which show the potential of D-glucuronic acid coated ultra-small GdMnO₃ nanoparticles as T₁ MRI contrast agents. The longitudinal (T₁) and transverse (T₂) relaxation times were also measured at various Gd (III) ion concentrations.

Conclusion

In summary, biocompatible and water soluble D-glucuronic acid coated ultrasmall GdMnO₃ nanoparticles were synthesized through a straight forward one step route. The size of the synthesized nanoparticles is around 3 nm, which is ultrasmall. We addressed the possibility of ultrasmall GdMnO₃ nanoparticles as a new MRI contrast agent by measuring their water proton relaxivities. Due to excellent relaxometric properties of Gd³⁺ and Mn³⁺ ion, they can provide the enhanced contrast for MR imaging. The ultrasmall GdMnO₃ nanoparticles exhibit r₁ = 13.40 mM⁻¹s⁻¹ and r₂ = 70.31 mM⁻¹s⁻¹ considering Gd³⁺ concentration, demonstrating that the nanoparticles can act as efficient T₁ contrast agent and T₁ MR images reflects the relaxivity value by providing bright images. It also exhibited clear dose-dependent contrast enhancement in its R₁ and map R₂ images Furthermore, because of using Mn³⁺ nanoparticles, the toxicity of ultrasmall GdMnO₃ nanoparticles is also decreased than individual Gd₂O₃ nanoparticles and specifically, the synthesized ultrasmall GdMnO₃ nanoparticles are non-toxic up to 500 μM.




Figure 1. HRTEM images of ultrasmall GdMnO₃




Figure 2. XRD of GdMnO₃




Figure 3. FTIR of GdMnO₃




Figure 4. R₁ and R₂ relaxivity of GdMnO₃




Figure 5. In vitro T₁ (upper) and T₂ (below) map images.




Figure 7. Cytotoxicity test




Figure 7. In vivo image of liver. (Before and after injection)




Figure 8. In vivo image of Kidney. (Before and after injection)